A reasoned approach towards administering COVID-19 vaccines to pregnant women

Simple item page
dc.coverageDOI: 10.1002/pd.5985
dc.creatorPramanick, Angsumita
dc.creatorKanneganti, Abhiram
dc.creatorWong, Jing Lin Jeslyn
dc.creatorLi, Sarah Weiling
dc.creatorDimri, Pooja Sharma
dc.creatorMahyuddin, Aniza Puteri
dc.creatorKumar, Sailesh
dc.creatorIllanes, Sebastián
dc.creatorChan, Jerry Kok Yen
dc.creatorSu, Lin Lin
dc.creatorBiswas, Arijit
dc.creatorTambyah, Paul Anantharajah
dc.creatorHuang, Ruby Yun Ju
dc.creatorMattar, Citra Nurfarah Zaini
dc.creatorChoolani, Mahesh
dc.date2021
dc.date.accessioned2025-11-18T19:41:12Z
dc.date.available2025-11-18T19:41:12Z
dc.description<p>There are over 50 SARS-CoV-2 candidate vaccines undergoing Phase II and III clinical trials. Several vaccines have been approved by regulatory authorities and rolled out for use in different countries. Due to concerns of potential teratogenicity or adverse effect on maternal physiology, pregnancy has been a specific exclusion criterion for most vaccine trials with only two trials not excluding pregnant women. Thus, other than limited animal studies, gradually emerging development and reproductive toxicity data, and observational data from vaccine registries, there is a paucity of reliable information to guide recommendations for the safe vaccination of pregnant women. Pregnancy is a risk factor for severe COVID-19, especially in women with comorbidities, resulting in increased rates of preterm birth and maternal morbidity. We discuss the major SARS-CoV-2 vaccines, their mechanisms of action, efficacy, safety profile and possible benefits to the maternal-fetal dyad to create a rational approach towards maternal vaccination while anticipating and mitigating vaccine-related complications. Pregnant women with high exposure risks or co-morbidities predisposing to severe COVID-19 infection should be prioritised for vaccination. Those with risk factors for adverse effects should be counselled accordingly. It is essential to support patient autonomy by shared decision-making involving a risk-benefit discussion with the pregnant woman.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/3f0d9c4c-4469-4b93-aafc-0137f9b65d7a
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/51695
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.41 (2021) date: 2021-07-01 nr.8 p.1018-1035
dc.subjectCOVID-19 Vaccines
dc.subjectCOVID-19/immunology
dc.subjectFemale
dc.subjectHumans
dc.subjectPregnancy
dc.subjectPregnancy Complications, Infectious/immunology
dc.subjectSARS-CoV-2/immunology
dc.subjectVaccination/ethics
dc.subjectSDG 3 - Good Health and Well-being
dc.titleA reasoned approach towards administering COVID-19 vaccines to pregnant womeneng
dc.typeReview articleeng
dc.typeArtículo de revisiónspa
Files
Collections
PURE